Media contact

Global leaders failed, once again, to make people with TB a priority, further stalling progress in this fight.

Urgent need to scale up newer tools available today to save lives; and develop a fast, safe and simple cure for TB.

The report highlights sluggish global progress on TB, indicating that countries will not be able to meet their targets in the ‘End TB’ strategy at this slow pace.

Gilead’s price gouging for sofosbuvir blocks millions of people from getting treatment

MSF calls on Johnson & Johnson to make key drug bedaquiline affordable for all people who need it.

South Africa breaks the ‘silence’ period and negotiations are re-opened

MSF calls out ViiV Healthcare—a division of US and UK pharmaceutical corporations Pfizer and GlaxoSmithKline plus Japan’s Shionogi—for preventing children with HIV from getting child-appropriate formulations of a critical HIV medicine, dolutegravir.